Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy

Award Number: R21AR080936
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/06/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy - PROJECT SUMMARY/ABSTRACT Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle degenerative disease. Children with DMD become restricted to wheelchairs within the first decade of their lives and die within the third. There is no effective treatment available for this devastating disease. Key myogenic processes in DMD pathophysiology at the molecular level are not completely understood, hindering the development of therapies for DMD. To fill this knowledge gap, we have been investigating whether an emerging mode of post-transcriptional gene regulation, known as epitranscriptomics, plays a role in DMD pathogenesis. Epitranscriptomics is a dynamic process that regulates RNA stability, splicing, and translation by reversible chemical modifications of mRNAs. N6- methyladenosine (m6A) is the most abundant epitranscriptomic mark. The m6A marks are installed by methyltransferase like 3 (METTL3) and methyltransferase like 14 (METTL14) and erased by fat mass and obesity-associated (FTO) and alkylation repair homolog 5 (ALKBH5). Specific reader proteins selectively recognize m6A-modified mRNAs and control their fates. Our recent findings revealed that m6A mRNA methylation regulates myogenesis in DMD and that levels of the m6A writers, erasers, and m6A marks are tightly regulated during myoblast differentiation, muscle regeneration, and in DMD. These studies suggest that m6A mRNA methylation plays a pivotal role in DMD pathophysiology. Here, we propose to gain a deeper mechanistic insight into m6A mRNA methylation in DMD. We will perform a transcriptome-wide analysis to map m6A-modified mRNAs (methylome) in skeletal muscle stem cells (MuSCs), primary myoblasts, and skeletal muscle of a well- established mdx mouse model of DMD and its counterpart healthy mice. We will also map the m6A methylome in DMD patient-derived and healthy myoblasts to extend our conclusions to a more clinically relevant model system. We will mechanistically characterize a select subset of prioritized m6A target mRNAs, both previously associated with DMD, as well as the novel, to establish their link to muscle degeneration in DMD. Our proposed research will make a significant impact by revealing transcriptome-wide m6A target mRNAs in DMD and provide insights into DMD pathophysiology incurred by the dysregulation of this novel mechanism.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	1400 WASHINGTON AVE	ALBANY	NY	12222	ALBANY	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	1/6/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $200,383 )
2025	2025	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	1400 WASHINGTON AVE	ALBANY	NY	12222	ALBANY	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	3/5/2025	NON-COMPETING CONTINUATION	$185,922
2025	2025	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	1400 WASHINGTON AVE	ALBANY	NY	12222	ALBANY	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	5/14/2025	NON-COMPETING CONTINUATION	$14,461
														Subtotal = $200,383

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	1400 WASHINGTON AVE	ALBANY	NY	12222	ALBANY	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	3/8/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $171,967 )
2023	2023	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	1400 WASHINGTON AVE	ALBANY	NY	12222	ALBANY	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	3/6/2023	NEW	$171,967
														Subtotal = $171,967

Grand Total All Awards = $372,350

Top

All Categories

About

Search

Reports

Data Submission

Award Information

N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy

Award Number: R21AR080936

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/06/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer